Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares.
about
Medical Therapy of Active Ulcerative ColitisMesalamine in the treatment and maintenance of remission of ulcerative colitis2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center TrialNew Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and AdherenceBarriers to oral medication adherence for adolescents with inflammatory bowel disease.Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease.Perception gaps between patients with ulcerative colitis and healthcare professionals: an online surveyA multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis.Optimizing management of Crohn's disease within a project management framework: results of a pilot study.Current practice and perception of screening for medication adherence in inflammatory bowel disease.Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.Evaluation of a group-based behavioral intervention to promote adherence in adolescents with inflammatory bowel diseaseA comparison of self-reported analgesic use and detection of urinary ibuprofen and acetaminophen metabolites by means of metabonomics: the INTERMAP Study.Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trialTreatment adherence in adolescents with inflammatory bowel disease: the collective impact of barriers to adherence and anxiety/depressive symptoms.Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn's diseaseUpdate on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.The potential role of a self-management intervention for ulcerative colitis: a brief report from the ulcerative colitis hypnotherapy trialCost utility of inflammation-targeted therapy for patients with ulcerative colitis.Self-management in pediatric inflammatory bowel disease: A clinical report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.Transition of Care in Inflammatory Bowel Disease.Development and reliability of a correction factor for family-reported medication adherence: pediatric inflammatory bowel disease as an exemplar.Second Korean guidelines for the management of ulcerative colitis.Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients.Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review.MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease.Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis.Immunosuppressive and biologic therapy for ulcerative colitis.Ulcerative colitis: prevention of relapse.Current and emerging maintenance therapies for ulcerative colitis.Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients.Patterns and Predictors of Long-term Nonuse of Medical Therapy Among Persons with Inflammatory Bowel Disease.Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.Treatment Nonadherence in Inflammatory Bowel Disease: Identification, Scope, and Management Strategies.Patient education in a 14 month randomized trial fails to improve adherence in ulcerative colitis: Influence of demographic and clinical parameters on non-adherence.Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions.The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology.
P2860
Q26777729-11DB3BA4-26AD-4BA2-A1A9-93E93D79C4D3Q26865546-94AA72CD-7C83-4859-962A-6256050BCD4AQ33601419-D94FB2AB-6869-4E2F-93B7-5A75E17B5E86Q33916287-ED5DDA2F-93C6-4AA0-B76F-461EA9686F49Q33988555-03407866-5703-4E97-929A-A5F300B07CC3Q34037161-F184A28E-8B12-4984-A173-FFF17BB3C448Q34380612-8F8E99D0-A5C1-4A8E-9A57-AB0A4262E432Q34533594-9C86D6A3-FB3F-4899-872D-76202E6C7C14Q35036687-12992E3A-EF5B-4259-8A4E-CE70D4355519Q35167157-68ADA4E7-0741-4B77-8882-8CE412DA209CQ35193565-946CF80F-3736-455F-9B4E-AC4EA00D1E5BQ35600777-248A55C5-2037-4611-907A-50CF43D007D9Q35734321-816ABF69-0CF3-469E-902A-13DBD67A7E36Q35801582-6916644A-6A45-4247-9904-151139E0596FQ35835746-0BB22DE7-68E5-4969-B7A8-A44CA788950DQ36048409-31D58743-8419-4028-8C8D-F99482134841Q36144377-763F810A-1968-4222-B929-69F918643527Q36615895-2A9414C4-C4EE-4EB2-A4D6-6EF77A009AE0Q36815176-8C4981C6-EA11-4818-BB89-D9327BD989F8Q37046066-31D00AE8-1EFE-49C3-9B99-C5201E94982CQ37182818-5EE55664-00AB-4ECE-BDFE-87A5EB7E89B4Q37383507-19803BCE-FFA4-42B0-9100-100A6815B63EQ37662503-BB3FB1DD-62A3-49C4-9D48-E809F508CB7BQ37769255-E3E8B00C-E0A6-42FB-A62D-B5FCE3EA35D9Q37807362-ECB61DF9-FFD5-4085-B57F-163277FBB077Q37833064-6CAD58DB-CA76-4EC8-92A8-D53AFC649843Q37872783-697961FC-C02B-49B0-8728-5B2065995340Q37892884-7B50236F-CB22-415C-BA6F-031E69A5B945Q37926915-426261CB-C206-4271-A115-9EE5891C3D90Q38060831-915459ED-2983-4301-81FF-E2E20BDCE1CBQ38103628-DD53DAE9-8554-4FD5-97DC-FD1845581EC3Q38197719-99043A67-DE7D-4F09-AE79-381F9103E131Q38366837-BBF6B955-2B14-4EEC-9D10-D4E659D88E90Q38414777-8605CFE6-2B4F-4301-8D47-0DA69AE1B306Q38471121-8C2DD98D-C1B2-41FC-B421-48603573042AQ38583997-D9F01B94-833B-4054-898A-F7737D21461AQ38685956-78A00A86-8005-48AB-923E-9376539FAD86Q38735146-3B58DCAE-16D2-4C40-9793-912540F59BFAQ38768891-63EA6D71-D713-4CCB-ABF0-CC4EDA1EFF49Q38996677-D8AD26D0-7A54-4159-9985-BFE2FF38D6CA
P2860
Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systematic review: impact of n ...... of ulcerative colitis flares.
@en
Systematic review: impact of n ...... of ulcerative colitis flares.
@nl
type
label
Systematic review: impact of n ...... of ulcerative colitis flares.
@en
Systematic review: impact of n ...... of ulcerative colitis flares.
@nl
prefLabel
Systematic review: impact of n ...... of ulcerative colitis flares.
@en
Systematic review: impact of n ...... of ulcerative colitis flares.
@nl
P2093
P1476
Systematic review: impact of n ...... of ulcerative colitis flares.
@en
P2093
K Kaulback
P D R Higgins
P S Schoenfield
P2860
P304
P356
10.1111/J.1365-2036.2008.03865.X
P407
P577
2008-10-07T00:00:00Z